A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The DAL-302 (dal-GenE-2) trial

16244DAL-GENE-2Open (affiliates only)A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The DAL-302 (dal-GenE-2) trialDAL-302NCT05918861IndustrialAdultTreatmentOtherCase, Brian; Waksman, RonMedstar Southern Maryland Hospital Center : Lallo Yadeta; Medstar Washington Hospital Center : Michelle Singh15701Michelle SinghMichelle Singhmichelle.singh@medstar.net18209Lallo YadetaLallo YadetaLallo.Yadeta@medstar.net2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>